# Primary Adrenal Gland Lymphoma: Report of 13 Cases—A Retrospective Multicenter Polish Lymphoma Research Group Analysis

**Authors:** Magdalena Witkowska, Kacper Kościelny, Agnieszka Giza, Ryszard Swoboda, Joanna Drozd-Sokołowska, Dariusz Wołowiec

PMC · DOI: 10.3390/life16020230 · 2026-02-01

## TL;DR

This study reports on 13 rare cases of primary adrenal gland lymphoma in Poland, highlighting their clinical features and poor prognosis.

## Contribution

The largest Polish multicenter analysis of primary adrenal gland lymphoma cases, providing demographic and survival data.

## Key findings

- Primary adrenal gland lymphoma is extremely rare and predominantly diffuse large B-cell lymphoma.
- Most patients had systemic symptoms and poor survival outcomes despite treatment.
- Complete remission after initial treatment was linked to better survival rates.

## Abstract

Introduction: The existence of primary adrenal gland lymphoma (PAGL) has been debated due to lack of lymphoid tissue in the adrenal glands. PAGL is extremely rare, accounting for less than 1% of all types of lymphomas. The aim of this study was to analyze patients with PAGL in Polish population. Material and Methods: We retrospectively reviewed 13 adult patients with PAGL diagnosed in Polish Hematological Centers. Results: A total of 13 patients (5 women and 8 men) with PAGL were included into the study. The median age at the diagnosis was 69.1 years (range: 31–85). The most common histological type was diffuse large B-cell lymphoma (DLBCL)-12 patients, the remaining one was diagnosed with Hodgkin lymphoma (HL). In 7 patients (54%), the left adrenal gland was involved; in 3 patients (23.5%), the right adrenal gland was involved; and 3 patients (23.5%) had bilateral lymphoma. Systemic symptoms (B symptoms) were observed in 11 out of 13 patients (85%). Two patients (15%) were treated with chemotherapy alone and the remaining eleven patients (85%) with immune and chemotherapy together (85%). During the follow-up period, 11 patients died, 8 had relapsed or refractory disease (62%), and 3 patients (23%) had relapse in central nervous system (CNS). The median progression-free survival (PFS) was 14.63 months, while the median overall survival (OS) was 20.30 months. Adrenalectomy of the involved adrenal gland was associated with shorter PFS (p = 0.0165), with trend of shorter OS. Achieving complete remission (CR) after front line treatment was associated with significantly longer OS (p = 0.0239) and PFS (p = 0.0152). Conclusions: Adrenal glands are extremely rare as primary locations of extranodal lymphoma. The prognosis of PAGL is generally poor. In this study, we described demographic, clinical, and pathological characteristics as well as factors that may affect survival among these groups. So far, it is the largest polish multicenter experience describing patients with PAGL.

## Linked entities

- **Diseases:** lymphoma (MONDO:0003659), diffuse large B-cell lymphoma (MONDO:0018905), Hodgkin lymphoma (MONDO:0004952)

## Full-text entities

- **Genes:** BCL6 (BCL6 transcription repressor) [NCBI Gene 604] {aka BCL5, BCL6A, LAZ3, ZBTB27, ZNF51}, MME (membrane metalloendopeptidase) [NCBI Gene 4311] {aka CALLA, CD10, CMT2T, NEP, SCA43, SFE}, HLA-G (major histocompatibility complex, class I, G) [NCBI Gene 3135] {aka MHC-G}, PWWP3A (PWWP domain containing 3A, DNA repair factor) [NCBI Gene 84939] {aka EXPAND1, HSPC211, MUM-1, MUM1}, IRF4 (interferon regulatory factor 4) [NCBI Gene 3662] {aka IMD131, LSIRF, MUM1, NF-EM5, SHEP8}
- **Diseases:** abdominal tumor (MESH:D000008), death (MESH:D003643), adrenal metastases (MESH:D009362), nodular sclerosis (MESH:D008224), anemia (MESH:D000740), weight loss (MESH:D015431), thrombocytopenia (MESH:D013921), HD (MESH:D008228), aggressive (MESH:D010554), incidentalomas (MESH:C538238), PD (MESH:D018450), impaired renal function (MESH:D007674), lymph nodes (MESH:D000072717), Lymphoma (MESH:D008223), lymphomatous (MESH:D013967), DLBCL (MESH:D016403), CR (MESH:D012075), lumbar pain (MESH:D010146), injury to (MESH:D014947), hyponatremia (MESH:D007010), adrenal carcinoma (MESH:D000310), CNS-IPI (MESH:D002493), B (MESH:D006509), abdominal pain (MESH:D015746), solid tumors (MESH:D009369), adrenal insufficiency (MESH:D000309), plasmablastic lymphoma (MESH:D000069293), hypoalbuminemia (MESH:D034141), HL (MESH:D006689), adrenocortical insufficiency (MESH:D000224), adrenal myelolipoma (MESH:D018209), fatigue (MESH:D005221), adrenal infiltration (MESH:D017254), autoimmune adrenalitis (MESH:D001327), lymphadenopathy (MESH:D008206), GCB (MESH:D054331), vomiting (MESH:D014839), Adrenal Gland Lymphoma (MESH:D000307), fever (MESH:D005334), hypotension (MESH:D007022)
- **Chemicals:** A-AVD (-), FDG (MESH:D019788), rituximab (MESH:D000069283), creatinine (MESH:D003404), brentuximab vedotin (MESH:D000079963), DA (MESH:C025953), DA-EPOCH (MESH:C079446), Mtx (MESH:D008727)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941533/full.md

---
Source: https://tomesphere.com/paper/PMC12941533